Journal article
Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship
Abstract
Oral nintedanib is marketed for the treatment of idiopathic pulmonary fibrosis (IPF). While effective slowing fibrosis progression, as an oral medicine nintedanib is limited. To reduce side effects and maximize efficacy, nintedanib was reformulated as a solution for nebulization and inhaled administration. To predict effectiveness treating IPF, the nintedanib pharmacokinetic/pharmacodynamic relationship was dissected. Pharmacokinetic analysis …
Authors
Epstein-Shochet G; Pham S; Beck S; Naiel S; Mekhael O; Revill S; Hayat A; Vierhout M; Bardestein-Wald B; Shitrit D
Journal
Pulmonary Pharmacology & Therapeutics, Vol. 63, ,
Publisher
Elsevier
Publication Date
August 2020
DOI
10.1016/j.pupt.2020.101933
ISSN
1094-5539